Lanifibranor

Lanifibranor is a novel, orally active drug that is being developed for the treatment of fibrotic diseases. It is a pan-peroxisome proliferator-activated receptor (PPAR) agonist, which means it activates all three types of PPARs (PPARα, PPARδ, and PPARγ). These receptors play a crucial role in controlling the inflammatory and fibrotic processes that are involved in the development of fibrotic diseases.

Mechanism of Action

Lanifibranor works by activating PPARs, which are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism of higher organisms. By activating these receptors, Lanifibranor can help to reduce inflammation and fibrosis, which are key factors in the progression of fibrotic diseases.

Clinical Trials

Lanifibranor has undergone several clinical trials to evaluate its safety and efficacy in treating fibrotic diseases. In a Phase IIb clinical trial for the treatment of non-alcoholic steatohepatitis (NASH), Lanifibranor showed promising results, with a significant reduction in the progression of fibrosis and resolution of NASH without worsening of fibrosis.

Potential Applications

In addition to NASH, Lanifibranor is also being investigated for its potential use in treating other fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis (IPF). These diseases currently have limited treatment options, and Lanifibranor's unique mechanism of action could potentially provide a new therapeutic approach.

Side Effects

As with any drug, Lanifibranor has the potential to cause side effects. In clinical trials, the most common side effects reported were mild to moderate and included nausea, diarrhea, and abdominal pain. However, the overall safety profile of Lanifibranor has been deemed acceptable in clinical trials.

File:Lanifibranor.png

Chemical structure of Lanifibranor

See Also

• Peroxisome proliferator-activated receptor
• Non-alcoholic steatohepatitis
• Systemic sclerosis
• Idiopathic pulmonary fibrosis

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian